This program seeks to make Dr. Convit’s breast cancer immunotherapy a standard low cost treatment option for patients. Through partnerships with research and health centers, JCWO works to advance its clinical trials in the US, South America and Europe using the ConvitVax. Additionally, this program looks to further enhance the anti-tumor effect of the ConvitVax by testing it in combination with other breast cancer therapies, as well as evaluate it as a treatment for other types of malignant solid tumors. With this program we direct our efforts to develop accessible immunotherapy protocols that can be affordable for underprivileged patients who lack the possibility of entering new innovative treatments.

We aim to make this immunotherapy available to patients who do not have access to new innovative therapies and in some cases, to standard of care treatments.